Drug Trial Radar · NCT05293496
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Apr 19, 2022
Primary completion
Jun 24, 2025
Study completion Aug 26, 2025
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .
Conditions
- Advanced Solid Tumor
- Castration-Resistant Prostatic Cancer
- Malignant Melanoma
- Pancreatic Ductal Carcinoma
- Hepatocellular Cancer
- Epithelial Ovarian Cancer
- Renal Cell Carcinoma
Interventions
vobramitamab duocarmazineBiological
Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
lorigerlimabBiological
Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 2 years
- Number of participants with serious adverse events (SAEs)Time frame: Up to 2 years
- Number of participants with AEs leading to study treatment discontinuationTime frame: Up to 2 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
University of California, San Francisco
San Francisco, California
Florida Cancer Specialists and Research Institute
Sarasota, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Weill Cornell Medicine
New York, New York
Carolina BioOncology
Huntersville, North Carolina
Stephenson Cancer Center, The University of Oklahoma
Oklahoma City, Oklahoma
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.